Anomer bio
Founded 2024
Invested 2025
Anomer Bio is developing a new class of immunotherapies that allow the targeting of glycans instead of proteins. Built upon multi-omics datasets for glycan targets and a first-in-human clinical trial, Anomer Bio has developed a computational platform to design synthetic sugar therapeutics that reverse disease associated functions. The first application is in difficult to treat solid cancers but the therapeutic technology is applicable across immune and fibrotic diseases.